IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

• Data demonstrate the ability of single and repeat doses of INB-200, DeltEx drug-resistant immunotherapy (DRI) gamma-delta T cell therapy, to induce T cell persistence and a sustained immune response.
  
• A treated patient, with paired tissue biopsies, demonstrated infiltration of gamma-delta T cells 148 days following a single administration in Cohort 1.
  
• Updated patient, survival and enrollment data from the ongoing INB-200 study to be presented at the Society for Neuro-Oncology (SNO) Annual Meeting on November 17, 2023 from 7:30 PM – 9:30 PM PT (Abstract Number: CTIM-42).
  

NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today presented new biological correlative data from the ongoing Phase 1 clinical trial of INB-200 targeting newly diagnosed glioblastoma multiforme (GBM) in a poster presentation at the Society for Immunotherapy of Cancer’s (SITC) 38^th Annual Meeting.

Chemotherapy has remained a mainstay of solid tumor treatment. Alkylating agents such as temozolomide (TMZ) can directly kill chemotherapy-sensitive GBM cells but can also sensitize chemotherapy resistant tumor cells to immune recognition by upregulating stress-associated NKG2D ligands (NKG2DL) to drive immunogenicity. Unfortunately, the lymphodepleting effects of chemotherapy, such as TMZ, also kills T cells, and prevents an effective immune response to these stress targets. IN8bio’s DeltEx DRI gamma-delta T cells are designed to be resistant to chemotherapy, allowing them to remain functional and be used in combinations to create a strong synergistic tumor cell killing impact.

“Gamma-delta T cells are important in immune responses and their high levels are known to correlate with improved survival outcomes. Efficient immune reconstitution is pivotal for favorable outcomes in cancer patients. This new analysis sheds light on how our DeltEx DRI gamma-delta T cell approach may induce durable persistence and immune responses,” said William Ho, Co-founder and CEO. “These important insights will help inform the ongoing development of our DeltEx DRI therapies across a variety of solid and hematological tumors.